Indications and uses
temporarily protects and helps relieve chapped or cracked skin temporarily protects minor cuts scrapes burns
temporarily protects and helps relieve chapped or cracked skin temporarily protects minor cuts scrapes burns
Apply cream liberally as often as needed
Drug Facts
Dimethicone 1%
Skin protectant
For external use only
When Using This Product
Stop Use And Ask A Doctor If
Do Not Use On
Keep Out Of Reach Of Children
Apply cream liberally as often as needed
Water, Mineral Oil, White Petrolatum, Ceresin, Sorbitan Sesquioleate, Sorbitol, Lanolin Alcohol, Aluminum Hydroxide, Magnesium Hydroxide, BHT, Ethylhexylglycerin, Phenoxyethanol
M-F 9a-5p CST
1-877-725-7274
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 200010 | dimethicone 1 % Topical Cream | PSN | 2 |
| 1361692 | Neutraphorus Rex Skin Protectant 1 % Topical Cream | PSN | 2 |
| 1361692 | dimethicone 10 MG/ML Topical Cream [Neutraphorus Rex Skin Protectant] | SBD | 2 |
| 200010 | dimethicone 10 MG/ML Topical Cream | SCD | 2 |
| 200010 | dimethicone 1 % Topical Cream | SY | 2 |
| 1361692 | Neutraphorus Rex Skin Protectant 1 % Topical Cream | SY | 2 |
| 1361692 | Neutraphorus Rex Skin Protectant 10 MG/ML Topical Cream | SY | 2 |
| Class | Version | Type | Effective |
|---|---|---|---|
| DIMETHICONE Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20180813 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 50952-003-01 | 2019-11-27 | C162847 | 48780-1 | 9855d018-ead1-cd31-e053-dbdaa90ab51a | NeutrapHorus Rex ® SKIN PROTECTANT CREAM |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50952-003-01 | NeutrapHorus RexSkin Protectant | 57 g in 1 JAR | CREAM | 57 | 2 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Dimethicone | ACTIVE INGREDIENT | 92RU3N3Y1O | 2 | |
| Dimethicone | ACTIVE MOIETY | 92RU3N3Y1O | 2 | |
| Aluminum Hydroxide | INACTIVE INGREDIENT | 5QB0T2IUN0 | 2 | |
| Butylated Hydroxytoluene | INACTIVE INGREDIENT | 1P9D0Z171K | 2 | |
| Ceresin | INACTIVE INGREDIENT | Q1LS2UJO3A | 2 | |
| Ethylhexylglycerin | INACTIVE INGREDIENT | 147D247K3P | 2 | |
| Lanolin Alcohols | INACTIVE INGREDIENT | 884C3FA9HE | 2 | |
| Magnesium Hydroxide | INACTIVE INGREDIENT | NBZ3QY004S | 2 | |
| Mineral Oil | INACTIVE INGREDIENT | T5L8T28FGP | 2 | |
| Petrolatum | INACTIVE INGREDIENT | 4T6H12BN9U | 2 | |
| Phenoxyethanol | INACTIVE INGREDIENT | HIE492ZZ3T | 2 | |
| Sorbitan Sesquioleate | INACTIVE INGREDIENT | 0W8RRI5W5A | 2 | |
| Sorbitol | INACTIVE INGREDIENT | 506T60A25R | 2 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 50952-003 | 50952-003-01 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Dimethicone | 92RU3N3Y1O | ACTIB |
| Water | 059QF0KO0R | IACT |
| Mineral Oil | T5L8T28FGP | IACT |
| Petrolatum | 4T6H12BN9U | IACT |
| Ceresin | Q1LS2UJO3A | IACT |
| Sorbitan Sesquioleate | 0W8RRI5W5A | IACT |
| Sorbitol | 506T60A25R | IACT |
| Lanolin Alcohols | 884C3FA9HE | IACT |
| Aluminum Hydroxide | 5QB0T2IUN0 | IACT |
| Magnesium Hydroxide | NBZ3QY004S | IACT |
| Butylated Hydroxytoluene | 1P9D0Z171K | IACT |
| Ethylhexylglycerin | 147D247K3P | IACT |
| Phenoxyethanol | HIE492ZZ3T | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SPRAY / TOPICAL | 1379 mg | ||
| Magnesium Hydroxide | MAGNESIUM HYDROXIDE | NBZ3QY004S | TABLET, CHEWABLE / ORAL | 750 mg | ||
| Petrolatum | PETROLATUM | 4T6H12BN9U | CAPSULE, EXTENDED RELEASE / ORAL | 0.07 mg | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SPRAY / TOPICAL | 3 mg | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | CAPSULE, LIQUID FILLED / ORAL | 0.1 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | INJECTION / INTRASYNOVIAL | 45 %w/v | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SUSPENSION / AURICULAR (OTIC) | 0.5 %w/v | ||
| Petrolatum | PETROLATUM | 4T6H12BN9U | EMULSION / TOPICAL | 7.8 %w/w | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | CAPSULE / ORAL | 120 mg | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | GEL / TOPICAL | 8 mg | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | FILM, SOLUBLE / ORAL | 0.06 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | INJECTION, SOLUTION / INTRAVENOUS | 4050 mg | ||
| Petrolatum | PETROLATUM | 4T6H12BN9U | SUPPOSITORY / VAGINAL | 27 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | SUSPENSION / ORAL | 45000 mg | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | TABLET, ORALLY DISINTEGRATING / ORAL | 1 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SUSPENSION / OPHTHALMIC | 0.1 %w/w | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SWAB / TOPICAL | 0.5 %w/w | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SUPPOSITORY / RECTAL | NA | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SHAMPOO / TOPICAL | 0.1 %w/w | ||
| Phenoxyethanol | PHENOXYETHANOL | HIE492ZZ3T | GEL / TOPICAL | 14 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | INJECTION / SUBCUTANEOUS | 4.7 %w/v | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | GUM, CHEWING / BUCCAL | 5 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | SOLUTION, CONCENTRATE / ORAL | 300 mg/1ml | ||
| Magnesium Hydroxide | MAGNESIUM HYDROXIDE | NBZ3QY004S | CAPSULE, DELAYED RELEASE / ORAL | 6.7 mg | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SOLUTION, CONCENTRATE / ORAL | 0.1 mg/1ml | ||
| Phenoxyethanol | PHENOXYETHANOL | HIE492ZZ3T | CREAM, AUGMENTED / TOPICAL | 10 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SUSPENSION / TOPICAL | 82 %w/w | ||
| Petrolatum | PETROLATUM | 4T6H12BN9U | CAPSULE / VAGINAL | NA | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | GEL / TOPICAL | 2.5 %w/w | ||
| Magnesium Hydroxide | MAGNESIUM HYDROXIDE | NBZ3QY004S | TABLET, FILM COATED / ORAL | 43.4 mg | ||
| Petrolatum | PETROLATUM | 4T6H12BN9U | OINTMENT / OPHTHALMIC | 88.4 %w/w | ||
| Petrolatum | PETROLATUM | 4T6H12BN9U | AEROSOL, FOAM / TOPICAL | 7.9 %w/w | ||
| Sorbitol | SORBITOL | 506T60A25R | ELIXIR / ORAL | 833.3 mg | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SUPPOSITORY / RECTAL | 1 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | CAPSULE / ORAL | 1111 mg | ||
| Petrolatum | PETROLATUM | 4T6H12BN9U | OINTMENT / TOPICAL | 7275 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | SYSTEM / TOPICAL | 6300 mg | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | CREAM / TOPICAL | 6 mg | ||
| Phenoxyethanol | PHENOXYETHANOL | HIE492ZZ3T | LOTION / TOPICAL | 1 %w/w | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | GEL, METERED / TOPICAL | 4 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | SOLUTION / ORAL | 29268 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | LOTION / TOPICAL | 10.7 %w/w | ||
| Petrolatum | PETROLATUM | 4T6H12BN9U | OINTMENT / VAGINAL | 4084 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | TABLET, DELAYED RELEASE / ORAL | 0.01 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | CREAM / VAGINAL | 402 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | TABLET, COATED / ORAL | 1.5 mg | ||
| Petrolatum | PETROLATUM | 4T6H12BN9U | CREAM, AUGMENTED / TOPICAL | 26 %w/w | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | LOTION / TOPICAL | 1000 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | AEROSOL, FOAM / TOPICAL | 4.95 %w/w | ||
| Petrolatum | PETROLATUM | 4T6H12BN9U | OINTMENT, AUGMENTED / TOPICAL | 81.94 %w/w | ||
| Sorbitol | SORBITOL | 506T60A25R | CONCENTRATE / ORAL | 600 mg/1ml | ||
| Aluminum Hydroxide | ALUMINUM HYDROXIDE | 5QB0T2IUN0 | CAPSULE / ORAL | NA | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | TABLET, FOR SUSPENSION / ORAL | 0.1 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | TABLET, FILM COATED / ORAL | 5 mg | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SOLUTION / ORAL | 14 mg | ||
| Aluminum Hydroxide | ALUMINUM HYDROXIDE | 5QB0T2IUN0 | OINTMENT / TOPICAL | NA | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | PASTE, DENTIFRICE / DENTAL | 14 %w/w | ||
| Magnesium Hydroxide | MAGNESIUM HYDROXIDE | NBZ3QY004S | POWDER, FOR SUSPENSION / ORAL | 0.01 mg | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 0.02 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 8a3ce41f-e6c0-472f-868b-243d08962ad7 | b43c4b7a-c176-4c36-a8cf-32cb6e99cc04 | 2012-11-13 | Warnings | 8a3ce41f-e6c0-472f-868b-243d08962ad7 b43c4b7a-c176-4c36-a8cf-32cb6e99cc04 |
Adverse event summaries are temporarily unavailable. Other product information remains available.